Globally, the rise in research expenditures, deterioration in human health conditions and the need for novel and effective therapies have boosted the demand for drug discovery tools. In just the last few years, the drug discovery and development industry has undergone a major transition, with increased calls for efficient, user-friendly and affordable products. A new study by BCC Research examines all aspects of the drug discovery process, which consumes a major portion of drug development costs. Therefore, it is imperative for companies to use technologies that offer a high probability that their future drug product will be commercially successful.
The opioid epidemic continues as one of America’s greatest public health crises as healthcare officials, public officials and countless Americans struggle to prevent opioid abuse, addiction and death. In a blog from 2017, Laurie Sullivan explores how one solution, known as The Smart Pill Drug Delivery Device, could be used to curb the crisis. Another possible solution? Prescribing more non-opioid painkillers. Click here to be notified when the BCC Research report “Non-opioid Pain Treatment: Global Markets to 2022” publishes later this month.
Smart pills are increasingly influencing our health. They are noninvasive and have redefined diagnosis, disease monitoring, and treatment adherence. By 2021, US sales of smart pills may double, reaching $1.2 billion. The global market for smart pills is poised to exceed a 20% compound annual growth rate (CAGR) during the next five years, according to BCC Research’s recent study, Smart Pills: Applications and Global Markets. High-growth application areas include capsule endoscopy, patient monitoring, and delivery of therapeutic agents. The adoption of advanced ingestible medical sensor technologies is a key growth driver.
Initially approached with caution by healthcare organizations, cloud computing is becoming more widely adopted in this arena. As cost savings outweighed potential data protection concerns, cloud adoption in healthcare increased during 2017. Healthcare information technology (IT) systems are expensive to implement, update and maintain. Cloud economics changes that by shifting from individual budgets to cost-sharing models enabled by private, multitenant and in some cases, public clouds. These trends are shifting in favor of increased IT spending on cloud hardware, software and networks.
The development of novel enzyme inhibitors has led to effective therapeutic options for diseases that were once considered difficult to treat. A newly updated study by BCC Research finds that approvals of new molecular entities will drive the global market for enzyme inhibitors to $179.9 billion by 2022. Enzyme inhibitors offer therapeutic options for myriad illnesses, including HCV, HIV, cancer, gastrointestinal disease, cardiovascular disease, inflammatory disorders, rheumatoid arthritis, neurological disorders (depression, Parkinson’s disease, Alzheimer’s disease) and diabetes.
The continuous glucose monitoring market, introduced nearly 20 years ago, is presently experiencing strong growth as diabetics, physicians, hospitals and clinics witness the benefits these devices can lend to the management of glucose levels. The market now includes blood glucose monitors, diabetes test strips, insulin durable and patch pumps, glucose sensors, and transmitters and receivers. The global market for continuous glucose monitoring equipment is expected to top $20.6 billion by 2022, according to a new study by BCC Research, at a five-year compound annual growth rate (CAGR) of 10.1%.
Earlier this month, BCC Research hosted an event “Connected Medical Devices: Bridging the Gap Between Wearables and Clinical Applications” in Boston, MA. BCC Research Senior editors Michael Sullivan and Robert G. Hunter discussed the future of wearable medical devices, especially those that link clinical and consumer applications. In her blog post from August 2017, Laurie Sullivan writes about one Google spin-off coming ever closer to “bridging the gap.”
There has been increasing interest in botanical drugs, with many players investigating their commercial potential. According to BCC Research, the global market for plant-derived and botanical drugs is expected to reach $39.6 billion by 2022. Excluding botanicals, growth in the plant-derived drug market is in line with the overall pharmaceutical industry, given the presence of generics (including biosimilars). Patent expirations will necessitate medicinal compounds other than single chemical entities. Growth in the U.S. market for plant-derived drugs will reflect new cannabinoids and their overall expanded uses, as well as eventual brand line extensions.
Ahead of the January 2018 update on the report “3D Cell Cultures: Technologies and Global Markets,” we are resharing Laurie Sullivan’s blog from July. On January 24, 2018, the analyst Robert G. Hunter will present a Member Exclusive Webinar and Q&A session on this report. Purchase the report or become a Member to attend!
A higher incidence of chronic diseases worldwide and the demand for advanced medication adherence systems are fueling growth in this market, which has the potential to surpass $3.9 billion by 2021. A new study by BCC Research examines the industry’s prospects and technologies by disease applications and geographical regions.
With commercial applications in many fields, the total amino acid market in the United States is projected to approach $2.5 billion by 2022. Amino acids have important roles in food for human consumption, animal feed, cosmetics, medicines, biotechnology and some industrial applications. In dollar terms, the most important current applications are in animal feed and human food. The threeprimary categories of commercial amino acids in the United States—animal feeds, flavorants and specialty uses—comprise a market in excess of $1.9 billion. Accounting for 18% of global consumption, the U.S. market is forecast to expand at a compound annual growth rate of 4.8% from 2017 to 2022, according to a new study by BCC Research.